BioPharmSignal logoBioPharmSignal

Biotech News

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

Embecta (EMBC)EmbectaEarnings

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025. "Our fourth quarter results were largely in line with our

Related news

EMBCEmbecta2026-08-07 10:30 EST

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

EMBCEmbecta2026-05-05 10:30 EST

Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results

BLTEBelite Bio2026-08-13 01:45 EST

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

ALTAltimmune2026-08-12 11:30 EST

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

SGMTSagimet Biosciences2026-08-11 11:30 EST

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Embecta

Global Diabetes Care Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery. Its products are used by people who self-administer injectable therapies and by healthcare systems supporting diabetes management. Injection-Device Portfolio The company's core portfolio includes pen needles and...

Recent company news

EMBCEmbecta2026-08-07 10:30 EST

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

EMBCEmbecta2026-08-07 10:00 EST

embecta Announces Quarterly Cash Dividend

EMBCEmbecta2026-07-23 21:00 EST

embecta to Report Fiscal Third Quarter Financial Results

EMBCEmbecta2026-06-16 10:30 EST

embecta appoints Nimish Muzumdar as SVP and President, North America

EMBCEmbecta2026-06-01 21:00 EST

embecta to Participate in Investor Events

Stock data

Close
5.23 USD
Market cap
207.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States